

Yoshio Hamada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3641984/publications.pdf>

Version: 2024-02-01

48
papers

1,282
citations

304602

22
h-index

377752

34
g-index

53
all docs

53
docs citations

53
times ranked

1083
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and synthesis of highly active Alzheimer's β -secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 211-215.	1.0	98
2	A Novel Approach of Water-Soluble Paclitaxel Prodrug with No Auxiliary and No Byproduct: Design and Synthesis of Isotaxel. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3782-3784.	2.9	83
3	O ² N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides. <i>Biopolymers</i> , 2004, 76, 344-356.	1.2	74
4	Design and synthesis of potent β -secretase (BACE1) inhibitors with carboxylic acid bioisosteres. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2380-2386.	1.0	71
5	Design of Potent Aspartic Protease Inhibitors to Treat Various Diseases. <i>Archiv Der Pharmazie</i> , 2008, 341, 523-535.	2.1	60
6	β -Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4354-4359.	1.0	55
7	New water-soluble prodrugs of HIV protease inhibitors based on O ² N intramolecular acyl migration. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 4155-4167.	1.4	53
8	Recent progress in the drug discovery of non-peptidic BACE1 inhibitors. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 391-416.	2.5	49
9	Novel non-peptidic and small-sized BACE1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1654-1658.	1.0	46
10	The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 903-922.	2.5	46
11	De novo design of a nanopore for single-molecule detection that incorporates a β -hairpin peptide. <i>Nature Nanotechnology</i> , 2022, 17, 67-75.	15.6	44
12	No Auxiliary, No Byproduct Strategy for Water-Soluble Prodrugs of Taxoids: A Scope and Limitation of O ² N Intramolecular Acyl and Acyloxy Migration Reactions. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2655-2666.	2.9	43
13	Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O ² N intramolecular acyl migration: Design, synthesis and kinetic study. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 159-170.	1.4	42
14	Combination of Non-natural α -Amino Acid Derivatives and Allophenylnorstatine-Dimethylthiopropine Scaffold in HIV Protease Inhibitors Have High Efficacy in Mutant HIV. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2992-3004.	2.9	42
15	Design of water-soluble prodrugs of HIV protease inhibitors based on O ² N intramolecular acyl migration: Design, synthesis and kinetic study. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1649-1653.	1.0	40
16	Significance of interactions of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2435-2439.	1.0	36
17	Recent progress in prodrug design strategies based on generally applicable modifications. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1627-1632.	1.0	31
18	Role of Pyridines in Medicinal Chemistry and Design of BACE1 Inhibitors Possessing a Pyridine Scaffold. , 0, , .		31

#	ARTICLE	IF	CITATIONS
19	Advances in the identification of β -secretase inhibitors. Expert Opinion on Drug Discovery, 2013, 8, 709-731.	2.5	29
20	Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at the P1 position. Bioorganic and Medicinal Chemistry, 2010, 18, 3175-3186.	1.4	21
21	Effect of the acyl groups on β -N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2727-2730.	1.0	26
22	New directions for protease inhibitors directed drug discovery. Biopolymers, 2016, 106, 563-579.	1.2	26
23	Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating d-cysteine derivatives as P2/P3 moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4213-4217.	1.0	25
24	Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1130-1135.	1.0	24
25	BACE1 Inhibitor Peptides: Can an Infinitely Small k_{cat}/K_M Value Turn the Substrate of an Enzyme into Its Inhibitor? ACS Medicinal Chemistry Letters, 2012, 3, 193-197.	1.3	23
26	Structure-guided design and synthesis of novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4640-4644.	1.4	21
27	Novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4640-4644.	1.0	19
28	Novel β -amyloid aggregation inhibitors possessing a turn mimic. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1572-1576.	1.0	18
29	DNA G-Wire Formation Using an Artificial Peptide is Controlled by Protease Activity. Molecules, 2017, 22, 1991.	1.7	15
30	Peptides for Silica Precipitation: Amino Acid Sequences for Directing Mineralization. Protein and Peptide Letters, 2018, 25, 15-24.	0.4	15
31	Novel BACE1 inhibitors with a non-acidic heterocycle at the P1 position. Bioorganic and Medicinal Chemistry, 2013, 21, 6665-6673.	1.4	12
32	Structure-activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 618-623.	1.0	12
33	Aspartic protease inhibitors as drug candidates for treating various difficult-to-treat diseases. Amino Acids, Peptides and Proteins, 2014, , 114-147.	0.7	7
34	Determination of β -amylase using a new blocked substrate. Clinica Chimica Acta, 1995, 234, 177-179.	0.5	6
35	Site-specific control of multiple mineralizations using a designed peptide and DNA. Nanoscale, 2016, 8, 17081-17084.	2.8	6
36	Tetrapeptides, as small-sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1. Journal of Peptide Science, 2010, 16, 257-262.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Novel prodrugs with a spontaneous cleavable guanidine moiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1685-1689.	1.0	4
38	A novel N-terminal degradation reaction of peptides via N-amidination. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1690-1695.	1.0	4
39	Novel Purification Process for Amyloid Beta Peptide(1-40). <i>Processes</i> , 2020, 8, 464.	1.3	3
40	Synthesis of Peptide-Immobilized Magnetic Beads, and Peptide Reactivity Assay for Assessing Skin Sensitization Utilizing Chromophore. <i>Processes</i> , 2020, 8, 1257.	1.3	2
41	Development of a chromophore-solid phase peptide reaction assay (C-SPRA) for assessing skin sensitization <i>in vitro</i> . <i>Analyst</i> , 2020, 145, 3211-3216.	1.7	2
42	Racemization-free segment condensation based on the O-acyl isopeptide method: Toward a chemical protein synthesis on solid support. <i>Advances in Experimental Medicine and Biology</i> , 2009, 611, 161-162.	0.8	2
43	Discovery of BACE1 Inhibitors for the Treatment of Alzheimer's Disease. , 2017, , .		1
44	Editorial: Organic-Inorganic Hybrid Materials and Their Applications. <i>Protein and Peptide Letters</i> , 2018, 25, 2-3.	0.4	1
45	Mass Spectrometry-Based Solid Phase Peptide Reaction Assay for Detecting Allergenicity Using an Immobilized Peptide-Conjugating Photo-Cleavable Linker. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8332.	1.8	1
46	Isoacylpeptide Method for Long-Chain and Difficult Sequence-Containing Peptide Preparation. , 0, , .		0
47	Peptidomimetic Synthesis: Drug Discovery for Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2020, 2103, 215-223.	0.4	0
48	Design and Synthesis of β -Secretase Inhibitors: Optimization at the P4 and P1' Positions. , 2006, , 599-600.		0